BioMarin Pharmaceutical Inc. (BMRN)

83.63
0.47 0.56
NASDAQ
Prev Close 83.16
Open 82.93
Day Low/High 82.72 / 84.71
52 Wk Low/High 75.81 / 106.74
Volume 629.10K
Exchange NASDAQ
Shares Outstanding 178.37B
Market Cap 14.83B
Div & Yield N.A. (N.A)
BioMarin Has Juice Left in the Tank

BioMarin Has Juice Left in the Tank

The big downtrend line was broken decisively.

Chart of the Day: BioMarin Pharmaceutical

The big downtrend line was broken decisively.

Sell These 5 Toxic Stocks Now, Before It's Too Late

Sell These 5 Toxic Stocks Now, Before It's Too Late

These five stocks could be toxic to your portfolio in April.

Biomarin Pharmaceutical (BMRN) Strong On High Relative Volume Today

Biomarin Pharmaceutical (BMRN) Strong On High Relative Volume Today

Trade-Ideas LLC identified Biomarin Pharmaceutical (BMRN) as a strong on high relative volume candidate

3 Stocks Pushing The Drugs Industry Downward

3 Stocks Pushing The Drugs Industry Downward

TheStreet highlights 3 stocks pushing the drugs industry lower today.

A Rolling-Nowhere Market Gathers More Bears

A less-bullish view is starting to spread.

Biomarin Pharmaceutical (BMRN) Strong On High Relative Volume Today

Biomarin Pharmaceutical (BMRN) Strong On High Relative Volume Today

Trade-Ideas LLC identified Biomarin Pharmaceutical (BMRN) as a strong on high relative volume candidate

BioMarin PKU Drug Shows Mixed Results in Pivotal Study

BioMarin PKU Drug Shows Mixed Results in Pivotal Study

Based on these study results, BioMarin intends to file pegvaliase for approval with the FDA by the end of the year, 'subject to further discussions' with the agency.

Insider Trading Alert - BRT, BMRN And CSGS Traded By Insiders

Insider Trading Alert - BRT, BMRN And CSGS Traded By Insiders

Stocks with insider trader activity include BRT, BMRN and CSGS

Biotech Stock Mailbag: Biomarin PKU Preview, Celldex Post-Mortem

Biotech Stock Mailbag: Biomarin PKU Preview, Celldex Post-Mortem

TheStreet's Senior Columnist Adam Feuerstein answers reader questions about biotech stocks.

BMRN, INCY And ALXN, Pushing Drugs Industry Downward

BMRN, INCY And ALXN, Pushing Drugs Industry Downward

TheStreet highlights 3 stocks pushing the drugs industry lower today.

Jim Cramer Says BioMarin Is the Last Bear Market

Jim Cramer Says BioMarin Is the Last Bear Market

TheStreet’s Action Alerts PLUS Portfolio Manager Jim Cramer is keeping an eye on shares of BioMarin Pharmaceutical.

Jim Cramer: Bear Markets in Many Sectors Have Ended

Jim Cramer: Bear Markets in Many Sectors Have Ended

Cramer is watching the FANG stocks as well as BioMarin Pharmaceutical.

JPMorgan's 7 Best Stock Picks With Near-Term Catalysts

JPMorgan's 7 Best Stock Picks With Near-Term Catalysts

Looking for quick profit? Consider companies that have upcoming events that could boost their stock prices. Here are seven stocks chosen by JPMorgan with upcoming catalysts.

Biomarin Drug Provides 'Substantial Benefit' to Kids with Rare, Fatal Brain Disease

Biomarin Drug Provides 'Substantial Benefit' to Kids with Rare, Fatal Brain Disease

If approved, the Biomarin drug will become the first effective treatment for CLN2 disease, a form of Batten disease.

BioMarin Faces a Key Test of Rare Disease Pipeline

BioMarin Faces a Key Test of Rare Disease Pipeline

BioMarin Pharmaceuticals is entering a crucial two-month period in which the company's ability to internally develop new treatments for rare diseases will come under renewed investor scrutiny.

BioMarin Announces BioMarin RareConnections(TM) Rebranding And Consolidating BioMarin's Comprehensive Support And Services For Eligible Rare Disease Patients

BioMarin Announces BioMarin RareConnections(TM) Rebranding And Consolidating BioMarin's Comprehensive Support And Services For Eligible Rare Disease Patients

On Rare Disease Day, BioMarin Highlights Its Commitment to Patients With Morquio A, MPS VI and Phenylketonuria (PKU) and Their Caregivers With Personalized Resources

BioMarin Announces 21 Presentations At 12th Annual WORLDSymposium™ 2016 February 29-March 4 In San Diego, California: 6 Oral And 15 Poster

BioMarin Announces 21 Presentations At 12th Annual WORLDSymposium™ 2016 February 29-March 4 In San Diego, California: 6 Oral And 15 Poster

Oral Presentations Include Results From Phase 1/2 Study on Cerliponase Alfa in Children With CLN2 Disease, a Form of Batten Disease

Biomarin Pharmaceutical (BMRN) Down In After-Hours Trading

Biomarin Pharmaceutical (BMRN) Down In After-Hours Trading

Trade-Ideas LLC identified Biomarin Pharmaceutical (BMRN) as a post-market laggard candidate

Rally Generates Mixed Emotions So Far

The put/call ratio shows folks were not buying the rally, but rather were buying puts into the rally.

Trade-Ideas: Biomarin Pharmaceutical (BMRN) Is Today's Post-Market Leader Stock

Trade-Ideas: Biomarin Pharmaceutical (BMRN) Is Today's Post-Market Leader Stock

Trade-Ideas LLC identified Biomarin Pharmaceutical (BMRN) as a post-market leader candidate

BioMarin Pharmaceutical's Illness Could Be Cured

BMRN could re-base in the weeks and months ahead as downside looks limited. 

Today's Weak On High Volume Stock: Biomarin Pharmaceutical (BMRN)

Today's Weak On High Volume Stock: Biomarin Pharmaceutical (BMRN)

Trade-Ideas LLC identified Biomarin Pharmaceutical (BMRN) as a weak on high relative volume candidate

TheStreet Quant Rating: C- (Hold)